EFFECT OF SGLT-2 INHIBITORS, GLP-1 RECEPTOR AGONISTS ON CARDIOVASCULAR AND RENAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES, NAFLD, AND CHRONIC KIDNEY DISEASE: A REAL WORLD EVIDENCE

被引：0
|
作者：
Krishnan, Arunkumar
Mukherjee, Diptasree
Althwanay, Aldanah
Woreta, Tinsay A.
Alqahtani, Saleh A.
机构：
来源：
GASTROENTEROLOGY | 2024年 / 166卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1558
引用
收藏
页码：S474 / S475
页数：2
相关论文
共 50 条
  • [41] Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
    Moa Lugner
    Naveed Sattar
    Mervete Miftaraj
    Jan Ekelund
    Stefan Franzén
    Ann-Marie Svensson
    Björn Eliasson
    Cardiovascular Diabetology, 20
  • [42] GLP-1 agonists and SGLT-2 inhibitors in adults with sickle cell disease
    Sun, Ryan
    Srivastava, Anand
    Derebail, Vimal K.
    Han, Jin
    Molokie, Robert E.
    Gordeuk, Victor
    Saraf, Santosh L.
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (08) : 1610 - 1612
  • [43] Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes
    Kutz, Alexander
    Kim, Dae Hyun
    Wexler, Deborah J.
    Liu, Jun
    Schneeweiss, Sebastian
    Glynn, Robert J.
    Patorno, Elisabetta
    DIABETES CARE, 2023, 46 (11) : 2004 - 2014
  • [44] Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with/without albuminuria: A systematic review and network meta-analysis
    Kawai, Yuki
    Uneda, Kazushi
    Yamada, Takayuki
    Kinguchi, Sho
    Kobayashi, Kazuo
    Azushima, Kengo
    Kanaoka, Tomohiko
    Toya, Yoshiyuki
    Wakui, Hiromichi
    Tamura, Kouichi
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 183
  • [45] Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
    Baviera, Marta
    Foresta, Andreana
    Colacioppo, Pierluca
    Macaluso, Giulia
    Roncaglioni, Maria Carla
    Tettamanti, Mauro
    Fortino, Ida
    Genovese, Stefano
    Caruso, Irene
    Giorgino, Francesco
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [46] Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
    Marta Baviera
    Andreana Foresta
    Pierluca Colacioppo
    Giulia Macaluso
    Maria Carla Roncaglioni
    Mauro Tettamanti
    Ida Fortino
    Stefano Genovese
    Irene Caruso
    Francesco Giorgino
    Cardiovascular Diabetology, 21
  • [47] GLP-1 receptor agonists and SGLT-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients
    Zheng, K.
    Azhie, A.
    You, X.
    Naghibzadeh, M.
    Tan, E.
    Naimimohasses, S.
    Sridhar, V.
    Gupta, S.
    Chen, S.
    Dash, S.
    Jaeckel, E.
    Woo, M.
    Singh, S.
    Cherney, D.
    Bhat, M.
    LIVER TRANSPLANTATION, 2024, 30 : 42 - 42
  • [48] Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT-2 inhibitors or GLP-1 receptor agonists under routine care: the DARWIN-Renal study
    Fadini, G.
    Longato, E.
    Morieri, M.
    Del Prato, S.
    Avogaro, A.
    Solini, A.
    DIABETOLOGIA, 2024, 67 : S3 - S3
  • [49] Socioeconomic position and initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes - a Danish nationwide observational study
    Falkentoft, A. C.
    Andersen, J.
    Malik, M. E.
    Selmer, C.
    Gaede, P. H.
    Staehr, P. B.
    Hlatky, M. A.
    Fosboel, E.
    Koeber, L.
    Torp-Pedersen, C.
    Gislason, G. H.
    Gerds, T. A.
    Shou, M.
    Bruun, N. E.
    Ruwald, A. C.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2622 - 2622
  • [50] Type 1 diabetes: Prescription of GLP-1 receptor agonists and SGLT2 inhibitors
    Simon, Annika
    DIABETOLOGIE UND STOFFWECHSEL, 2025, 20 (01) : 23 - 23
12345